Appropriately managing the suite of cardiometabolic disorders has substantial clinical implications for cardiovascular health and prevention of cardiovascular disease (CVD). In the case of diabetes, dyslipidemias, and hypertension, achieving the goals of HbA1c <7%, LDL cholesterol <100 mg/dL, and blood pressure <140/90 sets the patient up with significant cardiovascular benefits, such as the prevention of downstream CVD, heart attack, heart failure, or stroke. Although there has always been a “disconnect” between what is known and what is actually done, on both clinician and patient levels, and at times, compromises have to be made to individualize treatments, there is still an awareness of the importance of managing the individual components of cardiometabolic disorders aggressively and effectively.
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Eliminating Enhanced PTCs Would Have Cascading Economic Impacts, Report Estimates
March 6th 2025Enhanced premium tax credits (PTCs) have made marketplace health insurance more affordable, and eliminating them could have sweeping impacts on consumers and the health care industry, according to a new report.
Read More